Veracyte (VCYT) Expected to Announce Earnings on Thursday

Veracyte (NASDAQ:VCYT) will likely be posting its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.44 per share and revenue of $144.5950 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18. The business had revenue of $139.07 million during the quarter, compared to analysts’ expectations of $130.36 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.Veracyte’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.31 EPS. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Price Performance

Shares of Veracyte stock traded up $0.62 on Tuesday, hitting $56.23. The company had a trading volume of 185,505 shares, compared to its average volume of 1,026,661. Veracyte has a twelve month low of $22.92 and a twelve month high of $60.91. The stock has a 50-day moving average of $52.91 and a 200-day moving average of $42.01. The firm has a market capitalization of $4.49 billion, a P/E ratio of 51.50 and a beta of 1.93.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Jefferies Financial Group assumed coverage on Veracyte in a report on Monday, April 13th. They set a “buy” rating and a $45.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Veracyte in a report on Wednesday, June 24th. Guggenheim lifted their target price on Veracyte from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Morgan Stanley boosted their target price on Veracyte from $37.00 to $47.00 and gave the company an “underweight” rating in a research note on Thursday, July 9th. Finally, Zacks Research cut shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.88.

Insiders Place Their Bets

In other news, Director Karin Eastham sold 3,729 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $52.89, for a total value of $197,226.81. Following the completion of the sale, the director directly owned 15,097 shares of the company’s stock, valued at $798,480.33. This trade represents a 19.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Annie Mcguire sold 3,176 shares of Veracyte stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $49.76, for a total value of $158,037.76. Following the transaction, the executive vice president owned 137,240 shares of the company’s stock, valued at $6,829,062.40. This represents a 2.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 206,696 shares of company stock worth $10,079,058 in the last three months. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Veracyte

Several hedge funds have recently added to or reduced their stakes in VCYT. AQR Capital Management LLC raised its position in shares of Veracyte by 3.9% in the fourth quarter. AQR Capital Management LLC now owns 28,293 shares of the biotechnology company’s stock valued at $1,191,000 after purchasing an additional 1,071 shares during the period. ExodusPoint Capital Management LP acquired a new position in Veracyte in the 4th quarter valued at about $966,000. XTX Topco Ltd bought a new position in Veracyte in the 4th quarter valued at about $962,000. Jump Financial LLC acquired a new stake in Veracyte during the fourth quarter worth approximately $883,000. Finally, MML Investors Services LLC boosted its holdings in shares of Veracyte by 18.5% during the fourth quarter. MML Investors Services LLC now owns 13,313 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 2,077 shares during the period.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.